Abstract 51P
Background
Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13. Fractionations to investigate early and four year late side effects of hypofractionated postmastectomy radiation therapy (HFRT-PM) of 39 Gy in 13 fractions over 3 weeks.
Methods
We retrospectively analyzed characteristics and outcomes of patients with stage II to III breast cancer treated with HFRT-PM between February 2019 and February 2023 during the COVID-19 pandemic. The selected patients did not have any previously diagnosed heart or lung disease. Treatment provided in 13 fractions of 3 Gy per fraction. The treatment techniques were applied by using 3-dimensional conformal radiation therapy and IMRT of the chest wall with regional nodal volume if required. The end point was freedom from any grade 3 or higher toxicities.
Results
We identified 730 patients with a median follow-up of 4 year. About two-third of the patient (66.6%) had the disease located in the left side. Regional nodal irradiation was done in 84.1% of patients. In multivariate analysis, regional lymph node involvement (≥4 nodes) was associated with worse locoregional control (hazard ratio, 1.68; 95% confidence interval, 1.06-2.67; P = .03) and overall survival (hazard ratio, 2.16; 95% confidence interval, 1.59-2.95; P < .001). The toxicities were acceptable. After a four-year follow -up, there are no grade 3 or 4 toxicities. The incidence of early skin reactions (13% grade 2) cardiac disorders (1.5%), and symptomatic lung fibrosis (1.7%) was low during follow-up. The cumulative rate of arm lymphedema was 2.1% and considered severe in 40 patients (0.05%).
Conclusions
The early results of this study show that HFRT-PM of 39 Gy in 13 fractions over 3 weeks seems safe, but long-term results need to be observed and highlighting the need for long-term follow-up and for randomized trials for hypofractionated radiation therapy postmastectomy especially for young patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract
173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract